Effect of onset of type 2 diabetes on risks of cardiovascular disease and heart failure among new Zealanders with impaired glucose tolerance over 25 years: tapered-matched landmark analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2002-
    • Subject Terms:
      Cardiovascular Diseases*/diagnosis ; Cardiovascular Diseases*/epidemiology ; Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/epidemiology ; Glucose Intolerance* ; Heart Failure*/diagnosis ; Heart Failure*/epidemiology; Male ; Humans ; New Zealand/epidemiology
    • Abstract:
      Background: This study aimed to examine the association between the incident onset of T2DM and 5- and 10-year risks of CVD and HF in people with IGT identified in primary care in South and West Auckland, New Zealand (NZ) between 1994 and 2019.
      Methods: We compared CVD and HF risks in patients with IGT and with/without T2D newly diagnosed within the exposure window (1-5 years). Tapered matching and landmark analysis (to account for immortal bias) were used to control for potential effects of known confounders.
      Results: Among 26,794 patients enrolled with IGT, 845 had T2D newly diagnosed within 5 years from enrolment (landmark date) and 15,452 did not have T2D diagnosed. Patients progressing to T2D (vs. those not progressing) had a similar 5-year risk for CVD (hazard ratio 1.19; 95% CI 0.61-2.32) but significantly higher 10-year risk of CVD (2.45(1.40-4.29)), 5-year risk of HF (1.94(1.20-3.12)) and 10-year risk of HF (2.84(1.83-4.39). The association between the onset of T2D and risk of 10-year risk of CVD, 5-year and 10-year risk of HF was more likely among men, the socioeconomically deprived, those currently smoking, patients with higher metabolic measures and/or those with lower renal function. Patients of NZ European ethnicity had a lower 10-year risk of CVD.
      Conclusions: The study suggests that the diagnosis of T2D mediates the risk of CVD and HF in people with IGT. The development of risk scores to identify and better manage individuals with IGT at high risk of T2D is warranted.
      (© 2023. The Author(s).)
    • References:
      N Z Med J. 2013 Mar 01;126(1370):23-42. (PMID: 23474511)
      Stat Med. 2011 Feb 20;30(4):377-99. (PMID: 21225900)
      Circulation. 2007 Jul 10;116(2):151-7. (PMID: 17576864)
      JAMA Intern Med. 2021 Apr 1;181(4):511-519. (PMID: 33555311)
      Cochrane Database Syst Rev. 2018 Oct 29;10:CD012661. (PMID: 30371961)
      Diabetes Care. 2006 Jan;29(1):26-31. (PMID: 16373891)
      Popul Health Metr. 2017 Apr 26;15(1):15. (PMID: 28446238)
      Diabetes Care. 2005 Jan;28(1):20-6. (PMID: 15616228)
      Lancet Glob Health. 2021 Feb;9(2):e209-e217. (PMID: 33069275)
      Lancet. 2011 Jul 2;378(9785):31-40. (PMID: 21705069)
      Control Clin Trials. 1983 Mar;4(1):43-52. (PMID: 6851582)
      Cardiovasc Diabetol. 2020 Oct 10;19(1):174. (PMID: 33038936)
      N Engl J Med. 2011 Mar 03;364(9):829-841. (PMID: 21366474)
      Diabetes Care. 2005 Apr;28(4):888-94. (PMID: 15793191)
      Arch Intern Med. 2004 Oct 25;164(19):2147-55. (PMID: 15505129)
      Am J Epidemiol. 2018 Jul 1;187(7):1530-1538. (PMID: 29584812)
      Diabetes Care. 2009 Feb;32(2):287-94. (PMID: 19017771)
      J Surg Res. 2018 Mar;223:259-260. (PMID: 29198604)
      Diabetes Obes Metab. 2021 Aug;23(8):1746-1753. (PMID: 33769672)
      Metabolism. 2019 Jul;96:46-55. (PMID: 31029770)
      BMJ Open Diabetes Res Care. 2020 Nov;8(2):. (PMID: 33214188)
      N Z Med J. 2006 Jun 02;119(1235):U1997. (PMID: 16751821)
      Diabetes Care. 2002 Dec;25(12):2165-71. (PMID: 12453955)
      Cardiovasc Diabetol. 2021 Mar 22;20(1):66. (PMID: 33752676)
      J Intern Med. 2019 Sep;286(3):326-340. (PMID: 31165572)
      Diabetologia. 1991 Dec;34(12):891-8. (PMID: 1778354)
      Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71. (PMID: 21586725)
      N Engl J Med. 2001 May 3;344(18):1343-50. (PMID: 11333990)
      N Z Med J. 2020 Sep 4;133(1521):14-27. (PMID: 32994634)
      Lancet. 2017 Apr 8;389(10077):1399-1409. (PMID: 28237263)
      Ann Intern Med. 2005 Mar 1;142(5):323-32. (PMID: 15738451)
      Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. (PMID: 29222373)
      Nutr Metab Cardiovasc Dis. 2022 Dec;32(12):2803-2810. (PMID: 36328837)
      Int J Epidemiol. 2011 Dec;40(6):1542-53. (PMID: 22158665)
      Diabetologia. 1998 Sep;41(9):1010-6. (PMID: 9754818)
      N Z Med J. 1997 Feb 28;110(1038):48-50. (PMID: 9076284)
      N Engl J Med. 2002 Feb 7;346(6):393-403. (PMID: 11832527)
      Lancet. 2010 Jun 26;375(9733):2215-22. (PMID: 20609967)
      N Z Med J. 1999 Sep 24;112(1096):361-3. (PMID: 10587056)
      Cardiovasc Diabetol. 2020 Mar 30;19(1):41. (PMID: 32228577)
      Front Endocrinol (Lausanne). 2022 Oct 07;13:1041808. (PMID: 36277718)
      JAMA Netw Open. 2022 Feb 1;5(2):e2147171. (PMID: 35129595)
      BMJ Open Diabetes Res Care. 2021 Aug;9(1):. (PMID: 34433547)
    • Contributed Indexing:
      Keywords: Cardiovascular diseases; Heart failure; Impaired glucose tolerance; Landmark analysis; Tapered matching; Type 2 diabetes
    • Publication Date:
      Date Created: 20230630 Date Completed: 20230703 Latest Revision: 20231122
    • Publication Date:
      20231215
    • Accession Number:
      PMC10314599
    • Accession Number:
      10.1186/s12933-023-01871-y
    • Accession Number:
      37391762